CME: HIV Prevention: The Role of Pre-Exposure Prophylaxis (HIV-PrEP)
Cost: FreeView Offer chevron_right
The development of antiretroviral therapy (ART) has had a dramatic impact on HIV-related morbidity and mortality. The use of ART in HIV-infected patients has been the core strategy to not only treat HIV but also prevent vertical HIV transmission. Antiretrovirals can be used for HIV prevention in patients who are not HIV-infected but are repeatedly exposed to HIV in a strategy termed pre-exposure prophylaxis (PrEP). Although the rationale for PrEP stems from successful HIV prevention in HIV exposed infants with the use of ART during labor, early post-partum period, and throughout breastfeeding, it has more recently applied to been applied to sexual transmission (e.g., people with multiple partners or HIV serodiscordant couples) and people who inject drugs illicitly with support from the literature. Because much of what comprises evidence and guidelines supporting PrEP has been published relatively recently and because healthcare professionals are oftentimes unable to keep up with the steady publishing of literature and evolution of clinical practice in a timely manner, continuing healthcare education activities in this area are warranted.
By the end of the session the participant will be able to:
- Define the role of pre-exposure prophylaxis (PrEP) including identification of high-risk patient populations for appropriate use
- Analyze the data that support the use of PrEP for the prevention of HIV infection and apply it to patient cases
- Assess the safety and efficacy of PrEP in the context of the medical literature and apply that knowledge to patient cases
- Describe recommendations for PrEP use and the limitations to PrEP, and apply them to patient cases
- Recall the economic impact of the widespread use of PrEP including benefits and limitations
Target Audience: The following healthcare professionals: infectious disease specialists, primary care physicians, and public health; physician assistants, nurse practitioners, nurses, and pharmacists who practice in infectious disease; and any other healthcare professionals with an interest in or who clinically encounter HIV.